The global fetal bovine serum market size reached USD 1.05 billion in 2024. The market is projected to reach USD 1.65 billion by 2033, exhibiting a growth rate (CAGR) of 4.85% during 2025-2033. The market growth is attributed to rising demand for biotechnology and drug research, expanding cell culture uses, drug development advances, increasing investments in regenerative medicine, the broadening of vaccine production, and the increased utilization of FBS in clinical trials and personalized medicine.
Fetal bovine serum (FBS) is a major component of animal cell culture media, which is obtained from bovine fetuses of cows. It has several nutritional and macromolecular factors that are essential for cell growth. Besides this, it also comprises amino acids, sugars, lipids, hormones, and low gamma globulin content. As a result, it is widely utilized in a range of applications, such as providing essential nutrients and facilitating cell survival and proliferation in eukaryotic cell culture. It is also used in research, manufacturing, biotech drugs, and controlling human and veterinary vaccines.
The market is propelled by the rising demand for high-quality serum in diagnostics, research, and pharmaceutical production. The growing biotechnology and pharmaceutical industries, combined with the increased emphasis on advanced therapeutic treatments, also enhance the market growth. Additionally, the advancements in serum-based research technologies and ongoing growth in biotechnology and life sciences are anticipated to raise market demand. Nonetheless, the FBS market has challenges regarding ethical issues of animal sourcing, regulatory barriers, and supply chain interruptions. These challenges that can be addressed are the development of substitutes for FBS. A research study published in May 2025 identified that milk whey can be used as a sustainable and efficient substitute for fetal bovine serum (FBS) in cell culture in the laboratory. Apart from this, researchers also seek novel ways to decrease the ethical footprint of sourcing, e.g., enhanced welfare standards in farm animal production.
2.What is the expected growth rate of the global fetal bovine serum market during 2025-2033?
3.What has been the impact of COVID-19 on the global fetal bovine serum market?
4.What are the key factors driving the global fetal bovine serum market?
5.What is the breakup of the global fetal bovine serum market based on the product?
6.What is the breakup of the global fetal bovine serum market based on the application?
7.What is the breakup of the global fetal bovine serum market based on the end user?
8.What are the key regions in the global fetal bovine serum market?
9.Who are the key players/companies in the global fetal bovine serum market?
Fetal bovine serum (FBS) is a major component of animal cell culture media, which is obtained from bovine fetuses of cows. It has several nutritional and macromolecular factors that are essential for cell growth. Besides this, it also comprises amino acids, sugars, lipids, hormones, and low gamma globulin content. As a result, it is widely utilized in a range of applications, such as providing essential nutrients and facilitating cell survival and proliferation in eukaryotic cell culture. It is also used in research, manufacturing, biotech drugs, and controlling human and veterinary vaccines.
The market is propelled by the rising demand for high-quality serum in diagnostics, research, and pharmaceutical production. The growing biotechnology and pharmaceutical industries, combined with the increased emphasis on advanced therapeutic treatments, also enhance the market growth. Additionally, the advancements in serum-based research technologies and ongoing growth in biotechnology and life sciences are anticipated to raise market demand. Nonetheless, the FBS market has challenges regarding ethical issues of animal sourcing, regulatory barriers, and supply chain interruptions. These challenges that can be addressed are the development of substitutes for FBS. A research study published in May 2025 identified that milk whey can be used as a sustainable and efficient substitute for fetal bovine serum (FBS) in cell culture in the laboratory. Apart from this, researchers also seek novel ways to decrease the ethical footprint of sourcing, e.g., enhanced welfare standards in farm animal production.
Fetal Bovine Serum Market Trends:
FBS finds application in generating stem cells for treating patients suffering from acute and chronic lung damage due to coronavirus disease (COVID-19). In addition, as it contains growth factors and antibodies that can be utilized in laboratories to keep cells alive for dividing, growing, and evolving, it plays a pivotal role in various scientific research. This, along with significant growth in the research and development (R&D) activities on account of increasing funding by governing and private agencies to introduce novel biopharmaceuticals, is catalyzing the demand for FBS worldwide. Furthermore, the escalating demand for biopharma products on account of the growing prevalence of acute and chronic diseases is contributing to the growth of the market. Apart from this, the emerging trend of nuclear families and inflating income levels are positively influencing pet ownership and humanization, which is resulting in the increasing adoption of companion animals across the globe. This, along with the rising consumption of animal-derived products, is anticipated to fuel the need for FBS in veterinary diagnostics and vaccines to prevent infectious diseases around the world.Key Market Segmentation:
The publisher provides an analysis of the key trends in each sub-segment of the global fetal bovine serum market report, along with forecasts at the global, regional and country level from 2025-2033. Our report has categorized the market based on product, application and end user.Breakup by Product:
- Charcoal Stripped
- Chromatographic
- Dialyzed Fetal Bovine Serum
- Exosome Depleted
- Stem Cell
- Others
Breakup by Application:
- Biopharmaceuticals
- Cell Culture
- Human and Animal Vaccine Production
- Others
Breakup by End User:
- Biotechnology and Pharmaceutical Companies
- Academic Institutes
- Research Laboratories
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Atlas Biologicals Inc., Biological Industries (Sartorius AG), Bio-Techne Corporation, BioWest, Bovogen Biologicals Pty Ltd., General Electric Company, HiMedia Laboratories, Merck KGaA, PAN-Biotech, Rocky Mountain Biologicals, TCS Biosciences Ltd and Thermo Fisher Scientific Inc.Key Questions Answered in This Report
1.What was the size of the global fetal bovine serum market in 2024?2.What is the expected growth rate of the global fetal bovine serum market during 2025-2033?
3.What has been the impact of COVID-19 on the global fetal bovine serum market?
4.What are the key factors driving the global fetal bovine serum market?
5.What is the breakup of the global fetal bovine serum market based on the product?
6.What is the breakup of the global fetal bovine serum market based on the application?
7.What is the breakup of the global fetal bovine serum market based on the end user?
8.What are the key regions in the global fetal bovine serum market?
9.Who are the key players/companies in the global fetal bovine serum market?
Table of Contents
1 Preface3 Executive Summary11 Value Chain Analysis13 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Fetal Bovine Serum Market
6 Market Breakup by Product
7 Market Breakup by Application
8 Market Breakup by End User
9 Market Breakup by Region
10 SWOT Analysis
12 Porters Five Forces Analysis
14 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Atlas Biologicals Inc.
- Biological Industries (Sartorius AG)
- Bio-Techne Corporation
- BioWest
- Bovogen Biologicals Pty Ltd.
- General Electric Company
- HiMedia Laboratories
- Merck KGaA
- PAN-Biotech
- Rocky Mountain Biologicals
- TCS Biosciences Ltd and Thermo Fisher Scientific Inc.